91Ë¿¹ÏÊÓƵ

I am a senior transplant surgeon with a long tome interest in organ transplantation outcomes and expanding the envelope of indication for transplantation and eligible organ donors. I am also interested in basic research and translational research that is focused on organ transplant tolerance, antibody mediated rejection, reperfusion injury, and xenotransplantation. In the past 10 years we have initiated a drug discovery program and this has resulted in a group of novel RORy inverse agonists that have shown promise in treating antibody mediated rejection, preventing MASH in a mouse model, and treating several cancers, Gastric, colorectal, hepatocellular, triple negative breast and pancreatic. The list is growing. The most fascinating novelty is that it is going to synergize with chemotherapy, immune checkpoint inhibitors, and perhaps other precision medicine targets because the effects are very novel and attacks the cancer by chocking off the myeloid compartment that is involved in delivering the suppressive immune cells such as neutrophils, macrophages and myeloid derived suppressor cells. this rebalance the tumour microenvironment and restores CD8 positive cytotoxic lymphocytes and NK cells. We have demonstrated this in preclinical hepatocellular and colorectal cancer and are hoping to do this in pancreatic, triple negative breast and prostate cancers.